Phase I Trial of Ruxolitinib in Combination With a Pediatric Based-regimen for Adolescents and Young Adults (AYAs) With Ph-like Acute Lymphoblastic Leukemia (ALL)
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 22 Oct 2018
At a glance
- Drugs Ruxolitinib (Primary) ; Cyclophosphamide; Cytarabine; Cytarabine; Dexamethasone; Doxorubicin; Mercaptopurine; Methotrexate; Methotrexate; Methotrexate; Pegaspargase; Pegaspargase; Tioguanine; Vincristine
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 11 Oct 2018 Planned End Date changed from 1 Sep 2025 to 5 Sep 2024.
- 11 Oct 2018 Planned primary completion date changed from 1 Sep 2022 to 5 Sep 2022.
- 11 Oct 2018 Planned initiation date changed from 1 Sep 2018 to 5 Sep 2019.